Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Derazantinib in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion

Trial Profile

A Phase 1/2 Study of Derazantinib in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Derazantinib (Primary)
  • Indications Cholangiocarcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Basilea Pharmaceutica
  • Most Recent Events

    • 30 Sep 2019 According to a Basilea Pharmaceutica media release, results of post hoc analysis were presented at the Annual Congress of the European Society for Medical Oncology (ESMO) 2019.
    • 30 Sep 2019 Results of post hoc analysis (n=44), presented in a Basilea Pharmaceutica media release.
    • 04 Jun 2019 Results of a post-hoc analysis assessing outcomes of patients treated with Derazantinib in 1L/2L compared to post-2L, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top